{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,9]],"date-time":"2026-01-09T21:18:07Z","timestamp":1767993487071,"version":"3.49.0"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2019,8,7]],"date-time":"2019-08-07T00:00:00Z","timestamp":1565136000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2019,8,7]],"date-time":"2019-08-07T00:00:00Z","timestamp":1565136000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100008373","name":"Takeda Pharmaceutical Company","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008373","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Adv Ther"],"published-print":{"date-parts":[[2019,10]]},"DOI":"10.1007\/s12325-019-01046-w","type":"journal-article","created":{"date-parts":[[2019,8,7]],"date-time":"2019-08-07T19:02:14Z","timestamp":1565204534000},"page":"2679-2696","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Hematopoietic Stem Cell Transplantation and Brentuximab Vedotin for Patients with Relapsed or Refractory Hodgkin Lymphoma and Systemic Anaplastic Large-Cell Lymphoma"],"prefix":"10.1007","volume":"36","author":[{"given":"Kenichi","family":"Ishizawa","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tomoko","family":"Yanai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2019,8,7]]},"reference":[{"key":"1046_CR1","doi-asserted-by":"publisher","first-page":"704","DOI":"10.1002\/ajh.25071","volume":"93","author":"SM Ansell","year":"2018","unstructured":"Ansell SM. Hodgkin lymphoma: 2018 update on diagnosis, risk-stratification, and management. Am J Hematol. 2018;93:704\u201315.","journal-title":"Am J Hematol"},{"key":"1046_CR2","doi-asserted-by":"publisher","first-page":"2065","DOI":"10.1016\/S0140-6736(02)08938-9","volume":"359","author":"N Schmitz","year":"2002","unstructured":"Schmitz N, Pfistner B, Sextro M, et al. Aggressive conventional chemotherapy compared with high-dose chemotherapy with autologous haemopoietic stem-cell transplantation for relapsed chemosensitive Hodgkin\u2019s disease: a randomised trial. Lancet. 2002;359:2065\u201371.","journal-title":"Lancet"},{"key":"1046_CR3","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1111\/j.1365-2141.2008.07349.x","volume":"143","author":"KS Peggs","year":"2008","unstructured":"Peggs KS, Anderlini P, Sureda A. Allogeneic transplantation for Hodgkin lymphoma. Br J Haematol. 2008;143:468\u201380.","journal-title":"Br J Haematol"},{"key":"1046_CR4","doi-asserted-by":"publisher","first-page":"4314","DOI":"10.1200\/JCO.2001.19.23.4314","volume":"19","author":"G Akpek","year":"2001","unstructured":"Akpek G, Ambinder RF, Piantadosi S, et al. Long-term results of blood and marrow transplantation for Hodgkin\u2019s lymphoma. J Clin Oncol. 2001;19:4314\u201321.","journal-title":"J Clin Oncol"},{"key":"1046_CR5","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1111\/ejh.12360","volume":"93","author":"TA Eyre","year":"2014","unstructured":"Eyre TA, Khan D, Hall GW, Collins GP. Anaplastic lymphoma kinase-positive anaplastic large cell lymphoma: current and future perspectives in adult and paediatric disease. Eur J Haematol. 2014;93:455\u201368.","journal-title":"Eur J Haematol"},{"key":"1046_CR6","doi-asserted-by":"publisher","first-page":"5496","DOI":"10.1182\/blood-2008-01-134270","volume":"111","author":"KJ Savage","year":"2008","unstructured":"Savage KJ, Harris NL, Vose JM, et al. ALK\u2212 anaplastic large-cell lymphoma is clinically and immunophenotypically different from both ALK+ ALCL and peripheral T-cell lymphoma, not otherwise specified: report from the International Peripheral T-Cell Lymphoma Project. Blood. 2008;111:5496\u2013504.","journal-title":"Blood"},{"key":"1046_CR7","doi-asserted-by":"publisher","first-page":"1458","DOI":"10.1182\/blood-2003-01-0039","volume":"102","author":"JA Francisco","year":"2003","unstructured":"Francisco JA, Cerveny CG, Meyer DL, et al. cAC10-vcMMAE, an anti-CD30-monomethyl auristatin E conjugate with potent and selective antitumor activity. Blood. 2003;102:1458\u201365.","journal-title":"Blood"},{"key":"1046_CR8","doi-asserted-by":"publisher","first-page":"2183","DOI":"10.1200\/JCO.2011.38.0410","volume":"30","author":"A Younes","year":"2012","unstructured":"Younes A, Gopal AK, Smith SE, et al. Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin\u2019s lymphoma. J Clin Oncol. 2012;30:2183\u20139.","journal-title":"J Clin Oncol"},{"key":"1046_CR9","doi-asserted-by":"publisher","first-page":"2190","DOI":"10.1200\/JCO.2011.38.0402","volume":"30","author":"B Pro","year":"2012","unstructured":"Pro B, Advani R, Brice P, et al. Brentuximab vedotin (SGN-35) in patients with relapsed or refractory systemic anaplastic large-cell lymphoma: results of a phase II study. J Clin Oncol. 2012;30:2190\u20136.","journal-title":"J Clin Oncol"},{"key":"1046_CR10","doi-asserted-by":"publisher","first-page":"840","DOI":"10.1111\/cas.12435","volume":"105","author":"M Ogura","year":"2014","unstructured":"Ogura M, Tobinai K, Hatake K, et al. Phase I\/II study of brentuximab vedotin in Japanese patients with relapsed or refractory CD30-positive Hodgkin\u2019s lymphoma or systemic anaplastic large-cell lymphoma. Cancer Sci. 2014;105:840\u20136.","journal-title":"Cancer Sci"},{"key":"1046_CR11","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1056\/NEJMoa1708984","volume":"378","author":"JM Connors","year":"2018","unstructured":"Connors JM, Jurczak W, Straus DJ, et al. Brentuximab vedotin with chemotherapy for stage III or IV Hodgkin\u2019s lymphoma. N Engl J Med. 2018;378:331\u201344.","journal-title":"N Engl J Med"},{"key":"1046_CR12","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1002\/1097-0142(197507)36:1<252::AID-CNCR2820360128>3.0.CO;2-7","volume":"36","author":"G Bonadonna","year":"1975","unstructured":"Bonadonna G, Zucali R, Monfardini S, De Lena M, Uslenghi C. Combination chemotherapy of Hodgkin\u2019s disease with adriamycin, bleomycin, vinblastine, and imidazole carboxamide versus MOPP. Cancer. 1975;36:252\u20139.","journal-title":"Cancer"},{"key":"1046_CR13","doi-asserted-by":"publisher","first-page":"2386","DOI":"10.1056\/NEJMoa022473","volume":"348","author":"V Diehl","year":"2003","unstructured":"Diehl V, Franklin J, Pfreundschuh M, et al. Standard and increased-dose BEACOPP chemotherapy compared with COPP-ABVD for advanced Hodgkin\u2019s disease. N Engl J Med. 2003;348:2386\u201395.","journal-title":"N Engl J Med"},{"key":"1046_CR14","doi-asserted-by":"publisher","first-page":"616","DOI":"10.1182\/blood.V97.3.616","volume":"97","author":"CH Moskowitz","year":"2001","unstructured":"Moskowitz CH, Nimer SD, Zelenetz AD, et al. A 2-step comprehensive high-dose chemoradiotherapy second-line program for relapsed and refractory Hodgkin disease: analysis by intent to treat and development of a prognostic model. Blood. 2001;97:616\u201323.","journal-title":"Blood"},{"key":"1046_CR15","doi-asserted-by":"publisher","first-page":"1628","DOI":"10.1093\/annonc\/mdf221","volume":"13","author":"A Josting","year":"2002","unstructured":"Josting A, Rudolph C, Reiser M, et al. Time-intensified dexamethasone\/cisplatin\/cytarabine: an effective salvage therapy with low toxicity in patients with relapsed and refractory Hodgkin\u2019s disease. Ann Oncol. 2002;13:1628\u201335.","journal-title":"Ann Oncol"},{"key":"1046_CR16","doi-asserted-by":"publisher","first-page":"1762","DOI":"10.1093\/annonc\/mdg496","volume":"14","author":"T Baetz","year":"2003","unstructured":"Baetz T, Belch A, Couban S, et al. Gemcitabine, dexamethasone and cisplatin is an active and non-toxic chemotherapy regimen in relapsed or refractory Hodgkin\u2019s disease: a phase II study by the National Cancer Institute of Canada Clinical Trials Group. Ann Oncol. 2003;14:1762\u20137.","journal-title":"Ann Oncol"},{"key":"1046_CR17","doi-asserted-by":"publisher","first-page":"3490","DOI":"10.1200\/JCO.2013.53.9593","volume":"32","author":"M Crump","year":"2014","unstructured":"Crump M, Kuruvilla J, Couban S, et al. Randomized comparison of gemcitabine, dexamethasone, and cisplatin versus dexamethasone, cytarabine, and cisplatin chemotherapy before autologous stem-cell transplantation for relapsed and refractory aggressive lymphomas: NCIC-CTG LY.12. J Clin Oncol. 2014;32:3490\u20136.","journal-title":"J Clin Oncol"},{"key":"1046_CR18","doi-asserted-by":"publisher","first-page":"1073","DOI":"10.3324\/haematol.2011.056051","volume":"97","author":"R Devillier","year":"2012","unstructured":"Devillier R, Coso D, Castagna L, et al. Positron emission tomography response at the time of autologous stem cell transplantation predicts outcome of patients with relapsed and\/or refractory Hodgkin\u2019s lymphoma responding to prior salvage therapy. Haematologica. 2012;97:1073\u20139.","journal-title":"Haematologica"},{"key":"1046_CR19","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1016\/S1470-2045(15)70013-6","volume":"16","author":"AJ Moskowitz","year":"2015","unstructured":"Moskowitz AJ, Sch\u00f6der H, Yahalom J, et al. PET-adapted sequential salvage therapy with brentuximab vedotin followed by augmented ifosamide, carboplatin, and etoposide for patients with relapsed and refractory Hodgkin\u2019s lymphoma: a non-randomised, open-label, single-centre, phase 2 study. Lancet Oncol. 2015;16:284\u201392.","journal-title":"Lancet Oncol"},{"key":"1046_CR20","doi-asserted-by":"publisher","first-page":"2136","DOI":"10.1016\/j.bbmt.2015.07.018","volume":"21","author":"R Chen","year":"2015","unstructured":"Chen R, Palmer JM, Martin P, et al. Results of a multicenter phase II trial of brentuximab vedotin as second-line therapy before autologous transplantation in relapsed\/refractory Hodgkin lymphoma. Biol Blood Marrow Transplant. 2015;21:2136\u201340.","journal-title":"Biol Blood Marrow Transplant"},{"key":"1046_CR21","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1111\/bjh.15539","volume":"183","author":"J Walewski","year":"2018","unstructured":"Walewski J, Hellmann A, Siritanaratkul N, et al. Prospective study of brentuximab vedotin in relapsed\/refractory Hodgkin lymphoma patients who are not suitable for stem cell transplant or multi-agent chemotherapy. Br J Haematol. 2018;183:400\u201310.","journal-title":"Br J Haematol"},{"key":"1046_CR22","doi-asserted-by":"publisher","first-page":"612","DOI":"10.1093\/annonc\/mdz009","volume":"30","author":"R Garcia-Sanz","year":"2019","unstructured":"Garcia-Sanz R, Sureda A, de la Cruz F, et al. Brentuximab vedotin and ESHAP is highly effective as second-line therapy for Hodgkin lymphoma patients (long-term results of a trial by the Spanish GELTAMO group). Ann Oncol. 2019;30:612\u201320.","journal-title":"Ann Oncol"},{"key":"1046_CR23","doi-asserted-by":"publisher","first-page":"e151","DOI":"10.3324\/haematol.2018.196899","volume":"104","author":"A Hagenbeek","year":"2019","unstructured":"Hagenbeek A, Mooij H, Zijlstra J, et al. Phase I dose-escalation study of brentuximab-vedotin combined with dexamethasone, high-dose cytarabine and cisplatin, as salvage treatment in relapsed\/refractory classical Hodgkin lymphoma: the HOVON\/LLPC Transplant BRaVE study. Haematologica. 2019;104:e151\u20133.","journal-title":"Haematologica"},{"key":"1046_CR24","first-page":"2806","volume":"130","author":"RD Cassaday","year":"2017","unstructured":"Cassaday RD, Fromm JR, Cowan AJ, et al. Radiographic and high-throughput sequencing (HTS)-based response assessment after brentuximab vedotin (BV) plus ifosfamide, carboplatin, and etoposide (ICE) for relapsed\/refractory (Rel\/Ref) classical Hodgkin lymphoma (cHL): updated results of a phase I\/II trial. Blood. 2017;130:2806 (Abstract).","journal-title":"Blood"},{"key":"1046_CR25","doi-asserted-by":"publisher","first-page":"1834","DOI":"10.1182\/blood-2016-03-704908","volume":"128","author":"R Cassaday","year":"2016","unstructured":"Cassaday R, Fromm J, Cowan A, et al. Safety and activity of brentuximab vedotin (BV) plus ifosfamide, carboplatin, and etoposide (ICE) for relapsed\/refractory (Rel\/Ref) classical Hodgkin lymphoma (cHL): initial results of a phase I\/II trial. Blood. 2016;128:1834 (Abstract).","journal-title":"Blood"},{"key":"1046_CR26","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1182\/blood-2017-11-815183","volume":"132","author":"AS LaCasce","year":"2018","unstructured":"LaCasce AS, Bociek RG, Sawas A, et al. Brentuximab vedotin plus bendamustine: a highly active first salvage regimen for relapsed or refractory Hodgkin lymphoma. Blood. 2018;132:40\u20138.","journal-title":"Blood"},{"key":"1046_CR27","doi-asserted-by":"publisher","first-page":"1183","DOI":"10.1182\/blood-2017-10-811224","volume":"131","author":"AF Herrera","year":"2018","unstructured":"Herrera AF, Moskowitz AJ, Bartlett NL, et al. Interim results of brentuximab vedotin in combination with nivolumab in patients with relapsed or refractory Hodgkin lymphoma. Blood. 2018;131:1183\u201394.","journal-title":"Blood"},{"key":"1046_CR28","doi-asserted-by":"publisher","first-page":"1635","DOI":"10.1182\/blood-2018-03-837633","volume":"132","author":"RH Advani","year":"2018","unstructured":"Advani RH, Moskowitz AJ, Bartlett NL, et al. Phase 1\/2 study of brentuximab vedotin in combination with nivolumab in patients with relapsed or refractory classic Hodgkin lymphoma: part 3 (concurrent dosing) results and updated progression-free survival results from parts 1 and 2 (staggered dosing). Blood. 2018;132:1635 (Abstract).","journal-title":"Blood"},{"key":"1046_CR29","doi-asserted-by":"publisher","first-page":"1529","DOI":"10.1016\/j.bbmt.2015.04.022","volume":"21","author":"M Afable","year":"2015","unstructured":"Afable M, Caimi PF, Hosing C, et al. Hematopoietic progenitor cell harvesting is feasible after treatment with brentuximab vedotin in CD30+ lymphoma patients who received multiple prior lines of treatment. Biol Blood Marrow Transplant. 2015;21:1529\u201331.","journal-title":"Biol Blood Marrow Transplant"},{"key":"1046_CR30","doi-asserted-by":"publisher","first-page":"703","DOI":"10.3109\/10428194.2014.930852","volume":"56","author":"T Illidge","year":"2015","unstructured":"Illidge T, Bouabdallah R, Chen R, et al. Allogeneic transplant following brentuximab vedotin in patients with relapsed or refractory Hodgkin lymphoma and systemic anaplastic large cell lymphoma. Leuk Lymphoma. 2015;56:703\u201310.","journal-title":"Leuk Lymphoma"},{"key":"1046_CR31","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1002\/hon.2119","volume":"32","author":"S Garciaz","year":"2014","unstructured":"Garciaz S, Coso D, Peyrade F, et al. Brentuximab vedotin followed by allogeneic transplantation as salvage regimen in patients with relapsed and\/or refractory Hodgkin\u2019s lymphoma. Hematol Oncol. 2014;32:187\u201391.","journal-title":"Hematol Oncol"},{"key":"1046_CR32","doi-asserted-by":"publisher","first-page":"574","DOI":"10.1111\/imj.13415","volume":"47","author":"H Mediwake","year":"2017","unstructured":"Mediwake H, Morris K, Curley C, Butler J, Kennedy G. Use of brentuximab vedotin as salvage therapy pre-allogeneic stem cell transplantation in relapsed\/refractory CD30 positive lympho-proliferative disorders: a single centre experience. Intern Med J. 2017;47:574\u20138.","journal-title":"Intern Med J"},{"key":"1046_CR33","doi-asserted-by":"publisher","first-page":"1853","DOI":"10.1016\/S0140-6736(15)60165-9","volume":"385","author":"CH Moskowitz","year":"2015","unstructured":"Moskowitz CH, Nademanee A, Masszi T, et al. Brentuximab vedotin as consolidation therapy after autologous stem-cell transplantation in patients with Hodgkin\u2019s lymphoma at risk of relapse or progression (AETHERA): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2015;385:1853\u201362.","journal-title":"Lancet"},{"key":"1046_CR34","doi-asserted-by":"publisher","first-page":"2639","DOI":"10.1182\/blood-2018-07-861641","volume":"132","author":"CH Moskowitz","year":"2018","unstructured":"Moskowitz CH, Walewski J, Nademanee A, et al. Five-year PFS from the AETHERA trial of brentuximab vedotin for Hodgkin lymphoma at high risk of progression or relapse. Blood. 2018;132:2639\u201342.","journal-title":"Blood"},{"key":"1046_CR35","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1001\/jamaoncol.2018.6278","volume":"5","author":"AS Kanate","year":"2019","unstructured":"Kanate AS, Kumar A, Dreger P, et al. Maintenance therapies for Hodgkin and non-Hodgkin lymphomas after autologous transplantation: a consensus project of ASBMT, CIBMTR, and the lymphoma working party of EBMT. JAMA Oncol. 2019;5:715\u201322.","journal-title":"JAMA Oncol"},{"key":"1046_CR36","doi-asserted-by":"publisher","first-page":"1313","DOI":"10.1038\/bmt.2016.129","volume":"51","author":"P Tsirigotis","year":"2016","unstructured":"Tsirigotis P, Danylesko I, Gkirkas K, et al. Brentuximab vedotin in combination with or without donor lymphocyte infusion for patients with Hodgkin lymphoma after allogeneic stem cell transplantation. Bone Marrow Transplant. 2016;51:1313\u20137.","journal-title":"Bone Marrow Transplant"},{"key":"1046_CR37","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1016\/j.critrevonc.2015.03.011","volume":"95","author":"PL Zinzani","year":"2015","unstructured":"Zinzani PL, Sasse S, Radford J, et al. Experience of brentuximab vedotin in relapsed\/refractory Hodgkin lymphoma and relapsed\/refractory systemic anaplastic large-cell lymphoma in the named patient program: review of the literature. Crit Rev Oncol Hematol. 2015;95:359\u201369.","journal-title":"Crit Rev Oncol Hematol"},{"key":"1046_CR38","doi-asserted-by":"publisher","first-page":"466","DOI":"10.3324\/haematol.2015.134213","volume":"101","author":"A Perrot","year":"2016","unstructured":"Perrot A, Monjanel H, Bouabdallah R, et al. Impact of post-brentuximab vedotin consolidation on relapsed\/refractory CD30+ Hodgkin lymphomas: a large retrospective study on 240 patients enrolled in the French named-patient program. Haematologica. 2016;101:466\u201373.","journal-title":"Haematologica"},{"key":"1046_CR39","doi-asserted-by":"publisher","first-page":"1562","DOI":"10.1182\/blood-2016-02-699850","volume":"128","author":"R Chen","year":"2016","unstructured":"Chen R, Gopal AK, Smith SE, et al. Five-year survival and durability results of brentuximab vedotin in patients with relapsed or refractory Hodgkin lymphoma. Blood. 2016;128:1562\u20136.","journal-title":"Blood"},{"key":"1046_CR40","doi-asserted-by":"publisher","first-page":"2709","DOI":"10.1182\/blood-2017-05-780049","volume":"130","author":"B Pro","year":"2017","unstructured":"Pro B, Advani R, Brice P, et al. Five-year results of brentuximab vedotin in patients with relapsed or refractory systemic anaplastic large cell lymphoma. Blood. 2017;130:2709\u201317.","journal-title":"Blood"},{"key":"1046_CR41","doi-asserted-by":"publisher","first-page":"1109","DOI":"10.1182\/blood-2016-06-723924","volume":"128","author":"R Garcia-Sanz","year":"2016","unstructured":"Garcia-Sanz R, Sureda A, Gonzalez AP, et al. Brentuximab vedotin plus ESHAP (BRESHAP) is a highly effective combination for inducing remission in refractory and relapsed Hodgkin lymphoma patients prior to autologous stem cell transplant: a trial of the Spanish group of lymphoma and bone marrow transplantation (GELTAMO). Blood. 2016;128:1109 (Abstract).","journal-title":"Blood"}],"container-title":["Advances in Therapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-019-01046-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s12325-019-01046-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-019-01046-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,21]],"date-time":"2024-07-21T20:04:11Z","timestamp":1721592251000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s12325-019-01046-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,8,7]]},"references-count":41,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2019,10]]}},"alternative-id":["1046"],"URL":"https:\/\/doi.org\/10.1007\/s12325-019-01046-w","relation":{},"ISSN":["0741-238X","1865-8652"],"issn-type":[{"value":"0741-238X","type":"print"},{"value":"1865-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,8,7]]},"assertion":[{"value":"5 March 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 August 2019","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}